Garfield Alastair 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Rhythm Pharmaceuticals (RYTM) CSO Alastair Garfield Receives RSU Award (6,663)
What Happened
Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals (RYTM), had 6,663 restricted stock units (RSUs) convert to common shares on February 1, 2026. Of those shares, 2,026 were withheld to cover tax withholding at $108.99 per share, generating $220,814. The net delivery to Garfield was 4,637 shares. The filing reflects the RSU vesting/conversion rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-01 (reported on Form 4 filed 2026-02-03).
- Vesting/Conversion: 6,663 RSUs converted to shares (reported as derivative exercise/conversion, code M).
- Tax withholding: 2,026 shares withheld (code F) at $108.99/share = $220,814.
- Net shares delivered to insider: 6,663 − 2,026 = 4,637 shares.
- Shares owned after transaction: Not specified in the provided filing.
- Footnotes:
- F1: Each RSU equals one share on settlement.
- F2: The 2,026 shares were withheld to pay withholding taxes upon vesting.
- F3: The RSUs vest 25% each year on Feb 1 of 2026–2029 and have no expiration.
- Filing timeliness: No late filing indication in the provided data (filed two days after the vesting date).
Context
This was a routine RSU vesting event with shares withheld to cover tax obligations (a common practice), not an active sale or purchase signaling a trade decision. The derivative entries reflect conversion of RSUs to common stock (exercise price $0.00), and the taxable liability was satisfied via share withholding rather than a cash payment.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-01+6,663→ 9,789 total - Tax Payment
Common Stock
[F2]2026-02-01$108.99/sh−2,026$220,814→ 7,763 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-02-01−6,663→ 19,987 total→ Common Stock (6,663 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein.
- [F3]The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date.